Health & Fitness
Health and Fitness
Health and Fitness
Thu, June 30, 2011Wed, June 29, 2011Tue, June 28, 2011Mon, June 27, 2011Sat, June 25, 2011Fri, June 24, 2011Thu, June 23, 2011Wed, June 22, 2011Tue, June 21, 2011Mon, June 20, 2011Sun, June 19, 2011Fri, June 17, 2011Thu, June 16, 2011Wed, June 15, 2011Tue, June 14, 2011Mon, June 13, 2011Fri, June 10, 2011Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Sat, June 4, 2011Fri, June 3, 2011Jubilant and Endo Pharmaceuticals Announce Late Stage Discovery Milestone in Oncology Program
Published on Monday, June 20th 2011 at 4:05 GMT by Market Wire
Jubilant and Endo Pharmaceuticals Announce Late Stage Discovery Milestone in Oncology Program -- BENGALURU, India, June 20, 2011 /PRNewswire/ --
Jubilant and Endo Pharmaceuticals Announce Late Stage Discovery Milestone in Oncology Program
BENGALURU, India, June 20, 2011 /PRNewswire/ --
Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals (Nasdaq: [ ENDP ]), of Chadds Ford, Pa, U.S.A., announced today that they have achieved a late stage discovery milestone in their joint program focused on cancer.
This is the third milestone in the two-year-old,multi-target, oncology focused partnership and enables the collaboration to rapidly pursue a development candidate. Endo and Jubilant had entered into a multiyear, multi-target oncology focused partnership in 2009. As a part of the partnership, Jubilant delivers preclinical development candidates and has an option to participate in clinical development. Endo owns the development and commercial rights to the successful outcomes. However, Jubilant derives research funding, development milestones and sales royalties on successful commercialization.
Commenting on this development, Sri Mosur, CEO& President, Global Drug Discovery & Development, Jubilant said: "We are pleased that we continue to enhance the portfolio outcomes for Endo Pharmaceuticals. It is an important achievement in our collaboration and demonstrates our scientist's commitment to Oncology research to deliver differentiated therapies to cancer patients worldwide. It will be our continued endeavor to support the collaboration in accelerating the development phase towards successful commercialization"
Sandeep Gupta, Sr. Vice President, Discovery and Early Development, Endo Pharmaceuticals commented: "We are pleased with the technical capabilities and productivity of the Jubilant team. They have done an outstanding job of designing novel molecules and todemonstrate preclinical proof of concept ahead of schedule. We look forward to nominating a development candidate in the near future."
About Us
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED. [ http://www.jubilantbiosys.com ]
Endo Pharmaceuticals is a US based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. [ http://www.endo.com ]
Contact For Business Queries
[ narendra_kumar@jubilantbiosys.com ]
+91-9611104886
SOURCE Jubilant Biosys Ltd
[ Back to top ]